Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease
Higuero Sevilla J, Memon A, Hinchcliff M. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Arthritis Research & Therapy 2023, 25: 118. PMID: 37422652, PMCID: PMC10329300, DOI: 10.1186/s13075-023-03090-y.Peer-Reviewed Original ResearchConceptsConnective tissue disease-associated interstitial lung diseaseInterstitial lung diseaseTreatment of patientsMycophenolate mofetilSSc-ILDLung diseaseClinical trialsScleroderma Lung Study IIPatient-reported outcome instrumentsIdiopathic inflammatory myositisClinical trial resultsInflammatory myositisIntravenous cyclophosphamideOral cyclophosphamideSubcutaneous tocilizumabGood tolerabilityLung functionSystemic sclerosisTreatment armamentariumRheumatoid arthritisPatient outcomesSimilar efficacyOutcome instrumentsPatientsUS FoodCorrection: Learnings from clinical trials in patients with connective tissue disease‑associated interstitial lung disease
Higuero Sevilla J, Memon A, Hinchcliff M. Correction: Learnings from clinical trials in patients with connective tissue disease‑associated interstitial lung disease. Arthritis Research & Therapy 2023, 25: 132. PMID: 37501068, PMCID: PMC10373245, DOI: 10.1186/s13075-023-03123-6.Peer-Reviewed Original ResearchConnective tissue disease-associated interstitial lung diseaseInterstitial lung diseaseLung diseaseClinical trialsPatientsDiseaseTrials